AGLE - Aeglea BioTherapeutics: Human Enzyme-Based Platform Tackles Multiple Rare Diseases
- Shares are trading under $10 IPO price, but the company has made significant progress with its human enzyme technology platform.
- Enterprise value is less than 1 times peak sales for their lead drug (in pivotal study) with data from a second more lucrative indication expected in the medium term.
- Drug development risk is somewhat lower here given preference for validated targets, smaller trials and assets rationally designed for indications of high unmet need.
- Pegzilarginase pivotal study seems derisked, with data coming in mid 2021. President/CEO has been accumulating shares as well.
- AGLE is a Buy. Possible Price Target is $15. Risk rating (1-5) is 2. Key risks include delays in the clinic, disappointing 2021 readout and competition.
For further details see:
Aeglea BioTherapeutics: Human Enzyme-Based Platform Tackles Multiple Rare Diseases